ADC Therapeutics SA, based in Lausanne, Switzerland, recently announced the treatment of 100 patients with relapsed or refractory diffuse large B-cell lymphoma (r/r DLBCL) using a selected dose of 150 µg/kg of ZYNLONTA® combined with glofitamab. The full data from this treatment is anticipated to be revealed in the fourth quarter of 2026. The company, known as a pioneer in this field, is listed on the NYSE under the ticker ADCT.